Australia is showing great interest in the availability of Retatrutide, a novel medication developed by Novo Nordisk. This combined-action drug, targeting both GLP-1 and GIP receptors, has shown significant efficacy in https://getsocialsource.com/story7469380/novo-nordisk-s-retatrutide-australia-a-new-hope-for-weight-management